NIH Ebola test vaccine shows promise in early trials

An experimental vaccine to prevent the Ebola virus has shown positive results among a 20-adult sample size, the National Institutes of Health (NIH) said in its January newsletter.

The newest vaccine was developed by scientists at the NIH Clinical Center in Bethesda, Maryland, and at GlaxoSmithKline. Development was based on knowledge gained from the earlier research.

In the latest study, the vaccine was well-tolerated, producing immune system responses in all 20 volunteers between the ages of 18 and 50. Ten received a lower-dose vaccine and 10 received a higher-dose vaccine. All 20 volunteers produced anti-Ebola antibodies within four weeks of receiving the vaccine, with antibody levels being higher in those individuals that received the higher-dose vaccine.

Based on these results, more research will be done to assess the safety and effectiveness of the vaccine. Additionally, no serious side effects were observed in any of the volunteers.

The vaccine also showed the creation of protective immune cells, known as CD8 T cells. Four weeks after vaccination, CD8 T cells were detected in two of the volunteers who had received the lower-dose vaccine and in seven people that had received the higher-dose vaccine.

Back in 2003, the NIH developed and also started supporting human testing of three experimental Ebola vaccines.

Organizations in this Story

National Institutes of Health

Want to get notified whenever we write about National Institutes of Health ?
Next time we write about National Institutes of Health, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.